Fcγ receptor–mediated cross-linking codefines the immunostimulatory activity of anti-human CD96 antibodies
Open Access
- 10 October 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (19)
Abstract
New strategies that augment T cell responses are required to broaden the therapeutic arsenal against cancer. CD96, TIGIT, and CD226 are receptors that bind to a communal ligand, CD155, and transduce either inhibitory or activating signals. The function of TIGIT and CD226 is established, whereas the role of CD96 remains ambiguous. Using a panel of engineered antibodies, we discovered that the T cell stimulatory activity of anti-CD96 antibodies requires antibody cross-linking and is potentiated by Fcγ receptors. Thus, soluble “Fc silent” anti-CD96 antibodies failed to stimulate human T cells, whereas the same antibodies were stimulatory after coating onto plastic surfaces. Remarkably, the activity of soluble anti-CD96 antibodies was reinstated by engineering the Fc domain to a human IgG1 isotype, and it was dependent on antibody trans -cross-linking by FcγRI. In contrast, neither human IgG2 nor variants with increased Fcγ receptor IIB binding possessed stimulatory activity. Anti-CD96 antibodies acted directly on T cells and augmented gene expression networks associated with T cell activation, leading to proliferation, cytokine secretion, and resistance to Treg suppression. Furthermore, CD96 expression correlated with survival in HPV + head and neck squamous cell carcinoma, and its cross-linking activated tumor-infiltrating T cells, thus highlighting the potential of anti-CD96 antibodies in cancer immunotherapy.Keywords
Funding Information
- Talix Therapeutics (2017/9)
This publication has 40 references indexed in Scilit:
- Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIaR131 and FcγRIIaH131Protein Engineering, Design and Selection, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Properties of mouse and human IgG receptors and their contribution to disease modelsBlood, 2012
- Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal AntibodyThe Journal of Immunology, 2011
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityProceedings of the National Academy of Sciences of the United States of America, 2009
- CD96 Interaction with CD155 via Its First Ig-like Domain Is Modulated by Alternative Splicing or Mutations in Distal Ig-like DomainsJournal of Biological Chemistry, 2009
- DNAX Accessory Molecule-1 Mediated Recognition of Freshly Isolated Ovarian Carcinoma by Resting Natural Killer CellsCancer Research, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- DNAM-1 and PVR Regulate Monocyte Migration through Endothelial JunctionsJournal of Experimental Medicine, 2004
- High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγRJournal of Biological Chemistry, 2001